{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T04:56:09Z","timestamp":1770526569956,"version":"3.49.0"},"reference-count":44,"publisher":"Portland Press Ltd.","issue":"2","license":[{"start":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T00:00:00Z","timestamp":1609891200000},"content-version":"vor","delay-in-days":5,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"}],"content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,1,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Brain renin\u2013angiotensin system (RAS) activation is thought to mediate deoxycorticosterone acetate (DOCA)-salt hypertension, an animal model for human primary hyperaldosteronism. Here, we determined whether brainstem angiotensin II is generated from locally synthesized angiotensinogen and mediates DOCA-salt hypertension. To this end, chronic DOCA-salt-hypertensive rats were treated with liver-directed siRNA targeted to angiotensinogen, the angiotensin II type 1 receptor antagonist valsartan, or the mineralocorticoid receptor antagonist spironolactone (n = 6\u20138\/group). We quantified circulating angiotensinogen and renin by enzyme-kinetic assay, tissue angiotensinogen by Western blotting, and angiotensin metabolites by LC-MS\/MS. In rats without DOCA-salt, circulating angiotensin II was detected in all rats, whereas brainstem angiotensin II was detected in 5 out of 7 rats. DOCA-salt increased mean arterial pressure by 19 \u00b1 1 mmHg and suppressed circulating renin and angiotensin II by &amp;gt;90%, while brainstem angiotensin II became undetectable in 5 out of 7 rats (&amp;lt;6 fmol\/g). Gene silencing of liver angiotensinogen using siRNA lowered circulating angiotensinogen by 97 \u00b1 0.3%, and made brainstem angiotensin II undetectable in all rats (P&amp;lt;0.05 vs. non-DOCA-salt), although brainstem angiotensinogen remained intact. As expected for this model, neither siRNA nor valsartan attenuated the hypertensive response to DOCA-salt, whereas spironolactone normalized blood pressure and restored brain angiotensin II together with circulating renin and angiotensin II. In conclusion, despite local synthesis of angiotensinogen in the brain, brain angiotensin II depended on circulating angiotensinogen. That DOCA-salt suppressed circulating and brain angiotensin II in parallel, while spironolactone simultaneously increased brain angiotensin II and lowered blood pressure, indicates that DOCA-salt hypertension is not mediated by brain RAS activation.<\/jats:p>","DOI":"10.1042\/cs20201239","type":"journal-article","created":{"date-parts":[[2021,1,10]],"date-time":"2021-01-10T18:29:24Z","timestamp":1610303364000},"page":"259-274","update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["No evidence for brain renin\u2013angiotensin system activation during DOCA-salt hypertension"],"prefix":"10.1042","volume":"135","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9138-6639","authenticated-orcid":false,"given":"Estrellita","family":"Uijl","sequence":"first","affiliation":[{"name":"Division of Vascular Medicine and Pharmacology, Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, The Netherlands"},{"name":"Division of Nephrology and Transplantation, Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liwei","family":"Ren","sequence":"additional","affiliation":[{"name":"Division of Vascular Medicine and Pharmacology, Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, The Netherlands"},{"name":"Translational Medicine Collaborative Innovation Center, The Second Clinical Medical College (Shenzhen People\u2019s Hospital) of Jinan University, Shenzhen, China"},{"name":"Department of Physiology, Shenzhen University Health Science Center, Shenzhen University, Shenzhen, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katrina\u00a0M.","family":"Mirabito Colafella","sequence":"additional","affiliation":[{"name":"Cardiovascular Program, Biomedicine Discovery Institute and Department of Physiology, Monash University, Melbourne, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"van Veghel","sequence":"additional","affiliation":[{"name":"Division of Vascular Medicine and Pharmacology, Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingrid\u00a0M.","family":"Garrelds","sequence":"additional","affiliation":[{"name":"Division of Vascular Medicine and Pharmacology, Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Domenig","sequence":"additional","affiliation":[{"name":"Attoquant Diagnostics, Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marko","family":"Poglitsch","sequence":"additional","affiliation":[{"name":"Attoquant Diagnostics, Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Zlatev","sequence":"additional","affiliation":[{"name":"Alnylam Pharmaceuticals, Cambridge, MA, U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae\u00a0B.","family":"Kim","sequence":"additional","affiliation":[{"name":"Alnylam Pharmaceuticals, Cambridge, MA, U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Huang","sequence":"additional","affiliation":[{"name":"Alnylam Pharmaceuticals, Cambridge, MA, U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren","family":"Melton","sequence":"additional","affiliation":[{"name":"Alnylam Pharmaceuticals, Cambridge, MA, U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewout\u00a0J.","family":"Hoorn","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Transplantation, Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Don","family":"Foster","sequence":"additional","affiliation":[{"name":"Alnylam Pharmaceuticals, Cambridge, MA, U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5052-3585","authenticated-orcid":false,"given":"A.H.\u00a0Jan","family":"Danser","sequence":"additional","affiliation":[{"name":"Division of Vascular Medicine and Pharmacology, Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"288","published-online":{"date-parts":[[2021,1,22]]},"reference":[{"key":"2021113011184286100_B1","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1016\/S0140-6736(18)32225-6","article-title":"Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: A systematic analysis for the global burden of disease study 2017","volume":"392","author":"Stanaway","year":"2018","journal-title":"Lancet (London, England)"},{"key":"2021113011184286100_B2","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1161\/01.CIR.96.7.2407","article-title":"Endothelial dysfunction and cardiorenal injury in experimental salt-sensitive hypertension: Effects of antihypertensive therapy","volume":"96","author":"Hayakawa","year":"1997","journal-title":"Circulation"},{"key":"2021113011184286100_B3","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1001\/jama.285.21.2719","article-title":"Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: A randomized controlled trial","volume":"285","author":"Agodoa","year":"2001","journal-title":"JAMA"},{"key":"2021113011184286100_B4","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/sj.jhh.1001127","article-title":"Why is plasma renin activity lower in populations of african origin?","volume":"15","author":"Sagnella","year":"2001","journal-title":"J. Hum. Hypertens."},{"key":"2021113011184286100_B5","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1124\/pr.59.3.3","article-title":"The intrarenal renin-angiotensin system: From physiology to the pathobiology of hypertension and kidney disease","volume":"59","author":"Kobori","year":"2007","journal-title":"Pharmacol. Rev."},{"key":"2021113011184286100_B6","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1681\/ASN.2011121159","article-title":"Liver angiotensinogen is the primary source of renal angiotensin ii","volume":"23","author":"Matsusaka","year":"2012","journal-title":"J. Am. Soc. Nephrol."},{"key":"2021113011184286100_B7","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1172\/JCI112566","article-title":"Angiotensinogen gene is expressed and differentially regulated in multiple tissues of the rat","volume":"78","author":"Campbell","year":"1986","journal-title":"J. Clin. Invest."},{"key":"2021113011184286100_B8","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1210\/endo-121-5-1616","article-title":"Cellular localization of angiotensinogen gene expression in brown adipose tissue and mesentery: Quantification of messenger ribonucleic acid abundance using hybridization in situ","volume":"121","author":"Campbell","year":"1987","journal-title":"Endocrinology"},{"key":"2021113011184286100_B9","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1161\/HYPERTENSIONAHA.115.06040","article-title":"Deficiency of angiotensinogen in hepatocytes markedly decreases blood pressure in lean and obese male mice","volume":"66","author":"Yiannikouris","year":"2015","journal-title":"Hypertension (Dallas, Tex.: 1979)"},{"key":"2021113011184286100_B10","doi-asserted-by":"publisher","first-page":"1470320316672348","DOI":"10.1177\/1470320316672348","article-title":"Adipocytes do not significantly contribute to plasma angiotensinogen","volume":"17","author":"Koizumi","year":"2016","journal-title":"J. Renin-Angiotensin-Aldosterone System: JRAAS"},{"key":"2021113011184286100_B11","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/S0031-6989(83)80059-9","article-title":"Cardiovascular responses of conscious doca-salt hypertensive rats to acute intracerebroventricular and intravenous administration of captopril","volume":"15","author":"Pochiero","year":"1983","journal-title":"Pharmacol. Res. Commun."},{"key":"2021113011184286100_B12","first-page":"H261","article-title":"Central renin-angiotensin system and the pathogenesis of doca-salt hypertension in rats","volume":"251","author":"Itaya","year":"1986","journal-title":"Am. J. Physiol."},{"key":"2021113011184286100_B13","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1291\/hypres.23.109","article-title":"Blockade of angiotensin receptors in the anterior hypothalamic preoptic area lowers blood pressure in doca-salt hypertensive rats","volume":"23","author":"Kubo","year":"2000","journal-title":"Hypertens. Res.: Off. J. Japanese Soc. Hypertens."},{"key":"2021113011184286100_B14","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1161\/HYPERTENSIONAHA.113.01743","article-title":"Circulating angiotensin ii gains access to the hypothalamus and brain stem during hypertension via breakdown of the blood-brain barrier","volume":"63","author":"Biancardi","year":"2014","journal-title":"Hypertension (Dallas, Tex.: 1979)"},{"key":"2021113011184286100_B15","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/ajh.2010.241","article-title":"Blockade of at1 receptors protects the blood-brain barrier and improves cognition in dahl salt-sensitive hypertensive rats","volume":"24","author":"Pelisch","year":"2011","journal-title":"Am. J. Hypertens."},{"key":"2021113011184286100_B16","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1093\/cvr\/cvx214","article-title":"Central and peripheral slow-pressor mechanisms contributing to angiotensin ii-salt hypertension in rats","volume":"114","author":"Lu","year":"2018","journal-title":"Cardiovasc. Res."},{"key":"2021113011184286100_B17","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1161\/01.RES.84.2.240","article-title":"Distinct renin isoforms generated by tissue-specific transcription initiation and alternative splicing","volume":"84","author":"Lee-Kirsch","year":"1999","journal-title":"Circ. Res."},{"key":"2021113011184286100_B18","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1161\/HYPERTENSIONAHA.116.08242","article-title":"Selective deletion of the brain-specific isoform of renin causes neurogenic hypertension","volume":"68","author":"Shinohara","year":"2016","journal-title":"Hypertension (Dallas, Tex.: 1979)"},{"key":"2021113011184286100_B19","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1161\/HYPERTENSIONAHA.116.08922","article-title":"Brain renin-angiotensin system: Does it exist?","volume":"69","author":"van Thiel","year":"2017","journal-title":"Hypertension (Dallas, Tex.: 1979)"},{"key":"2021113011184286100_B20","doi-asserted-by":"publisher","first-page":"16958","DOI":"10.1021\/ja505986a","article-title":"Multivalent n-acetylgalactosamine-conjugated sirna localizes in hepatocytes and elicits robust rnai-mediated gene silencing","volume":"136","author":"Nair","year":"2014","journal-title":"J. Am. Chem. Soc."},{"key":"2021113011184286100_B21","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1097\/HJH.0b013e32833d01ae","article-title":"Beneficial cardiac effects of the renin inhibitor aliskiren in spontaneously hypertensive rats","volume":"28","author":"van Esch","year":"2010","journal-title":"J. Hypertens."},{"key":"2021113011184286100_B22","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1161\/HYPERTENSIONAHA.119.12703","article-title":"Strong and sustained antihypertensive effect of small interfering rna targeting liver angiotensinogen","volume":"73","author":"Uijl","year":"2019","journal-title":"Hypertension (Dallas, Tex.: 1979)"},{"key":"2021113011184286100_B23","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1161\/01.HYP.29.6.1240","article-title":"Renin-angiotensin system components in the interstitial fluid of the isolated perfused rat heart. Local production of angiotensin i","volume":"29","author":"de Lannoy","year":"1997","journal-title":"Hypertension"},{"key":"2021113011184286100_B24","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1097\/HJH.0b013e32834bbcbf","article-title":"Urinary renin, but not angiotensinogen or aldosterone, reflects the renal renin-angiotensin-aldosterone system activity and the efficacy of renin-angiotensin-aldosterone system blockade in the kidney","volume":"29","author":"van den Heuvel","year":"2011","journal-title":"J. Hypertens."},{"key":"2021113011184286100_B25","doi-asserted-by":"publisher","first-page":"33678","DOI":"10.1038\/srep33678","article-title":"Neprilysin is a mediator of alternative renin-angiotensin-system activation in the murine and human kidney","volume":"6","author":"Domenig","year":"2016","journal-title":"Sci. Rep."},{"key":"2021113011184286100_B26","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.jacc.2016.11.064","article-title":"Roles of angiotensin peptides and recombinant human ace2 in heart failure","volume":"69","author":"Basu","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"2021113011184286100_B27","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1021\/acs.jmedchem.7b01147","article-title":"Facile synthesis, geometry, and 2\u2032-substituent-dependent in vivo activity of 5\u2032-(e)- and 5\u2032-(z)-vinylphosphonate-modified sirna conjugates","volume":"61","author":"Parmar","year":"2018","journal-title":"J. Med. Chem."},{"key":"2021113011184286100_B28","doi-asserted-by":"publisher","first-page":"31334","DOI":"10.1016\/S0021-9258(18)31697-1","article-title":"Angiotensinogen-deficient mice with hypotension","volume":"269","author":"Tanimoto","year":"1994","journal-title":"J. Biol. Chem."},{"key":"2021113011184286100_B29","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.1093\/ndt\/gfp225","article-title":"Transcutaneous measurement of glomerular filtration rate using fitc-sinistrin in rats","volume":"24","author":"Schock-Kusch","year":"2009","journal-title":"Nephrol. Dialysis, Transplantation: Off. Publ. Eur. Dialysis Transplant Assoc. - Eur. Renal Assoc."},{"key":"2021113011184286100_B30","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1038\/ki.2013.453","article-title":"Podocyte injury enhances filtration of liver-derived angiotensinogen and renal angiotensin ii generation","volume":"85","author":"Matsusaka","year":"2014","journal-title":"Kidney Int."},{"key":"2021113011184286100_B31","doi-asserted-by":"publisher","first-page":"R539","DOI":"10.1152\/ajpregu.00594.2004","article-title":"Nuclear localization of angiotensinogen in astrocytes","volume":"288","author":"Sherrod","year":"2005","journal-title":"Am. J. Physiol. Regulatory, Integrative Comparative Physiol."},{"key":"2021113011184286100_B32","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S0196-9781(98)00054-0","article-title":"Receptor-mediated angiotensin ii transcytosis by brain microvessel endothelial cells","volume":"19","author":"Rose","year":"1998","journal-title":"Peptides"},{"key":"2021113011184286100_B33","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1161\/01.HYP.0000125143.73301.94","article-title":"Adjacent expression of renin and angiotensinogen in the rostral ventrolateral medulla using a dual-reporter transgenic model","volume":"43","author":"Lavoie","year":"2004","journal-title":"Hypertension (Dallas, Tex.: 1979)"},{"key":"2021113011184286100_B34","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3109\/10641968509074755","article-title":"Angiotensin ii in the brain and brainstem of the doca salt hypertensive rat","volume":"7","author":"Weyhenmeyer","year":"1985","journal-title":"Clin. Exp. Hypertens. Part A, Theory Pract."},{"key":"2021113011184286100_B35","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1161\/HYPERTENSIONAHA.114.04458","article-title":"Intracerebroventricular infusion of the (pro)renin receptor antagonist pro20 attenuates deoxycorticosterone acetate-salt-induced hypertension","volume":"65","author":"Li","year":"2015","journal-title":"Hypertension (Dallas, Tex.: 1979)"},{"key":"2021113011184286100_B36","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1159\/000211202","article-title":"Angiotensinergic regulation of autonomic and neuroendocrine outputs: Critical roles for the subfornical organ and paraventricular nucleus","volume":"89","author":"Ferguson","year":"2009","journal-title":"Neuroendocrinology"},{"key":"2021113011184286100_B37","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/0167-0115(93)90438-E","article-title":"Antisense inhibition of at1 receptor mrna and angiotensinogen mrna in the brain of spontaneously hypertensive rats reduces hypertension of neurogenic origin","volume":"49","author":"Gyurko","year":"1993","journal-title":"Regul. Pept."},{"key":"2021113011184286100_B38","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1161\/01.HYP.25.3.314","article-title":"Antisense inhibition of hypertension in the spontaneously hypertensive rat","volume":"25","author":"Wielbo","year":"1995","journal-title":"Hypertension (Dallas, Tex.: 1979)"},{"key":"2021113011184286100_B39","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/S0006-8993(99)01375-X","article-title":"Antisense inhibition of angiotensinogen attenuates vasopressin release in the paraventricular hypothalamic nucleus of spontaneously hypertensive rats","volume":"829","author":"Kagiyama","year":"1999","journal-title":"Brain Res."},{"key":"2021113011184286100_B40","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1161\/01.HYP.31.6.1317","article-title":"Reduction of cold-induced hypertension by antisense oligodeoxynucleotides to angiotensinogen mrna and at1-receptor mrna in brain and blood","volume":"31","author":"Peng","year":"1998","journal-title":"Hypertension (Dallas, Tex.: 1979)"},{"key":"2021113011184286100_B41","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1161\/01.HYP.37.2.371","article-title":"Antisense inhibition of brain renin-angiotensin system decreased blood pressure in chronic 2-kidney, 1 clip hypertensive rats","volume":"37","author":"Kagiyama","year":"2001","journal-title":"Hypertension (Dallas, Tex.: 1979)"},{"key":"2021113011184286100_B42","doi-asserted-by":"publisher","first-page":"4661","DOI":"10.1007\/s00216-019-01771-9","article-title":"A microanalytical capillary electrophoresis mass spectrometry assay for quantifying angiotensin peptides in the brain","volume":"411","author":"Lombard-Banek","year":"2019","journal-title":"Anal. Bioanal. Chem."},{"key":"2021113011184286100_B43","doi-asserted-by":"publisher","first-page":"8163","DOI":"10.1007\/s00216-019-02162-w","article-title":"Letter to the editor regarding \u201ca microanalytical capillary electrophoresis mass spectrometry assay for quantifying angiotensin peptides in the brain","volume":"411","author":"Danser","year":"2019","journal-title":"Anal. Bioanal. Chem."},{"key":"2021113011184286100_B44","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1161\/HYPERTENSIONAHA.113.02893","article-title":"Multiple ascending dose study with the new renin inhibitor vtp-27999: Nephrocentric consequences of too much renin inhibition","volume":"63","author":"Balcarek","year":"2014","journal-title":"Hypertension (Dallas, Tex.: 1979)"}],"container-title":["Clinical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/135\/2\/259\/902582\/cs-2020-1239.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/135\/2\/259\/902582\/cs-2020-1239.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T12:16:36Z","timestamp":1638274596000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/clinsci\/article\/135\/2\/259\/227513\/No-evidence-for-brain-renin-angiotensin-system"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,1,29]]}},"URL":"https:\/\/doi.org\/10.1042\/cs20201239","relation":{},"ISSN":["0143-5221","1470-8736"],"issn-type":[{"value":"0143-5221","type":"print"},{"value":"1470-8736","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,1]]},"published":{"date-parts":[[2021,1]]}}}